Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Sinsuda Dechsupa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Osteoarthritis and Musculoskeleton, Department of Biochemistry, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Ch…. Hauptthemen laut MEDLINE: Quality of Life, Dietary Supplements, Vitamin D, Vitamin D Deficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Degenerative lumbar disease is a significant contributor to acute or chronic musculoskeletal issues in the elderly, often associated with low serum 25‐hydroxyvitamin D (25(OH)D) levels. The effect of vitamin D 2 supplementation on muscle mass, strength, and physical performance remains unclear. This study aimed to determine the effect of vitamin D 2 supplementation on these parameters in patients with degenerative lumbar disease and low vitamin D status. A total of 115 patients with serum 25(OH)D levels < 30 ng/mL were administered 40,000 IU of vitamin D 2 (ergocalciferol) weekly for 6 months. Body composition, serum 25(OH)D, parathyroid hormone (PTH) levels, muscle strength, and physical performance were examined before and after 6 months of vitamin D 2 supplementation. Baseline median serum 25(OH)D was 24.9 ng/mL; 79.1% had vitamin D insufficiency, and 20.9% had vitamin D deficiency. After supplementation, median 25(OH)D increased to 43.1 ng/mL ( p < 0.001), with a significant reduction in PTH ( p < 0.001). Significant improvements were observed in muscle mass ( p = 0.04), balance test ( p = 0.01), gait speed ( p = 0.009), chair stand test ( p < 0.001), short physical performance ( p < 0.001), Oswestry disability index ( p < 0.001), and visual analog scale (VAS) scores ( p < 0.001). Post‐supplementation 25(OH)D levels correlated negatively with body mass index ( ρ = −0.187, p = 0.045), fat mass ( ρ = −0.219, p = 0.019), fat percentage ( ρ = −0.199, p = 0.033), and VAS score ( ρ = −0.313, p < 0.001). Six months of vitamin D 2 supplementation significantly improved vitamin D status, muscle mass, physical performance, and quality of life in patients with degenerative lumbar disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Excellence in Osteoarthritis and Musculoskeleton, Department of Biochemistry, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Biomechanics and Innovative Spine Surgery, Department of Orthopaedics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
- Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Wicharn Yingsakmongkol, Sittisak Honsawek
Zitieren
APA
Dechsupa, S., Yingsakmongkol, W., Limthongkul, W., Singhatanadgige, W., Assawakosri, S., & Honsawek, S. (2025). Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease. Clinical and Translational Science. https://doi.org/10.1111/cts.70315
Vancouver
Dechsupa S, Yingsakmongkol W, Limthongkul W, Singhatanadgige W, Assawakosri S, Honsawek S. Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease. Clinical and Translational Science. 2025. doi:10.1111/cts.70315
BibTeX
@article{Dechsupa2025,
author = {Dechsupa, Sinsuda and Yingsakmongkol, Wicharn and Limthongkul, Worawat and Singhatanadgige, Weerasak and Assawakosri, Suvichada and Honsawek, Sittisak},
title = {Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70315}
}
EUVIMED